Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche And Recursion’s AI Drug Discovery Pact To Focus On Neuroscience

Another Boost For AI

Executive Summary

The 10-year deal aims to use artificial intelligence to map out the cellular biology behind neuroscience and oncology and accelerate drug discovery in another boost to the field.

You may also be interested in...



Amgen Joins AI/ML Gold Rush With Generate Deal

Deal Snapshot: At a same-day conference, Amgen’s CEO outlined the importance of AI/ML to the company’s drug development strategy, as numerous large biopharma companies have recently made similar deals.

AstraZeneca And BenevolentAI Advance AI Partnership With Second Novel Target

AstraZeneca and BenevolentAI claim their partnership is augmenting and accelerating validation of new drug targets.

Deal Watch: Lilly Teams With Regor On Metabolic Disorders

Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel